계정 가입
이미 존재한 계정
가입을 클릭하여 코인타임의 <a class="underline" href="#term-of-service">서비스 약관</a> 과 a class="underline" href="#privacy-policy">개인정보 보호 정책</a> . 에 동의함.
email 로 로그인
email 로 가입
사용자 이메일
수신함을 확인하세요
중의 링크를 통해 로그인 하세요
중의 링크를 통해 가입 하세요
Annovis Bio
company
About
Annovis Bio develops novel treatments for Alzheimer’s disease, Parkinson’s disease, and other neurodegenerative disorders.
- 1 - 10
Details
- Last Funding Type
- Series A
- Last Funding Money Raised
- $5.70M
- Industries
- Biotechnology,Developer Platform,Therapeutics
- Founded date
- Jan 1, 2008
- Number Of Employee
- 1 - 10
- Operating Status
- Active
Annovis Bio is specialty pharmaceutical company founded to develop novel treatments for Alzheimer’s disease (AD), Parkinson’s disease (PD) and other neurodegenerative disorders. The company has two compounds in clinical development: Posiphen® targets early stage AD and PD and may stop or slow the progression of the disease; BNC targets late stage AD and may stabilize the decline.
Funding Rounds
Number of Funding Rounds
Total Funding Amount
1
$5.70M
Annovis Bio has raised a total of
$5.70M
in funding over 2 rounds. Their latest funding was raised on
May 26, 2015 from a Series A round.
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| May 26, 2015 | Series A | $5.70M | 1 | — | — | Detail |
Investors
Number of Lead Investors
Number of Investors
—
1
Annovis Bio is funded by 1 investors.
Keiretsu Forum
are the most recent investors.
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
Keiretsu Forum
|
— | Series A |
Share
Twitter
LinkedIn
Line
Facebook
Telegram
Email
Page Link
